Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.680
0.00 (0.00%)
Jul 15, 2026, 4:00 PM EDT - Market closed
Gain Therapeutics Employees
As of December 31, 2025, Gain Therapeutics had 21 total employees, including 20 full-time and 1 part-time employees. The number of employees decreased by 4 or -16.00% compared to the previous year.
Employees
21
Change (1Y)
-4
Growth (1Y)
-16.00%
Revenue / Employee
n/a
Profits / Employee
-$1,011,418
Market Cap
71.66M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | -4 | -16.00% | 20 | 1 |
| Dec 31, 2024 | 25 | -7 | -21.88% | 23 | 2 |
| Dec 31, 2023 | 32 | 1 | 3.23% | 29 | 3 |
| Dec 31, 2022 | 31 | 2 | 6.90% | 28 | 3 |
| Dec 31, 2021 | 29 | 15 | 107.14% | 25 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| Gossamer Bio | 162 |
| Heron Therapeutics | 128 |
| XBiotech | 87 |
| Rani Therapeutics Holdings | 71 |
| Pliant Therapeutics | 49 |
| Entera Bio | 22 |
| iBio, Inc. | 20 |
GANX News
- 16 days ago - Gain Therapeutics receives FDA clearance of GT-02287 IND application - TheFly
- 16 days ago - Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease - GlobeNewsWire
- 4 weeks ago - Gain Therapeutics Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference - Transcripts
- 5 weeks ago - Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - GlobeNewsWire
- 5 weeks ago - Gain Therapeutics Slides: Corporate presentation - Filings
- 7 weeks ago - Gain Therapeutics presents data from Phase 1b study of GT-02287 - TheFly
- 7 weeks ago - Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026 - GlobeNewsWire
- 2 months ago - Gain Therapeutics price target lowered to $8 from $10 at Roth Capital - TheFly